Command Palette
Search for a command to run...
Par Drugs & Chemicals
NSE: PARPHARMACEUTICALS & BIOTECHNOLOGYPHARMACEUTICALS
Market Cap
--
P/E Ratio
0.00
P/B Ratio
0.00
ROE
0.00%
ROA
0.00%
Debt/Equity
0.00
Book Value
₹0.0
EPS
₹0.0
About Par Drugs & Chemicals
Par Drugs & Chemicals primarily engaged in manufacturing of Active Pharma Ingredients and fine chemicals (API) for domestic market as well as for exports to international markets.
Par Drugs and Chemicals Limited was originally incorporated as a Private Limited Company with the name "Par Drugs and Chemicals Private Limited" at Bhavnagar, Gujarat on 26 February 1999. Subsequently, the Company was converted into a Public Limited Company and the name of the Company was changed to "Par Drugs and Chemicals Limited" on 5 November 2018. The Company began in 1982 under the vision of the founder, Late Shri Vallabhbhai J. Savani. The Company discontinued its existing pharmaceutical and chemical operations and diversified into an entirely new vertical line of business. With shareholder approval, the Company is investing in real estate & construction, clean & renewable energy, and capital markets. At present, Company is engaged in manufacturing of Active Pharma Ingredients and fine chemicals (API) for domestic market as well as for exports to international markets. APIs, also known as "bulk drugs" or "bulk actives" are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients. There are four Manufacturing Blocks at Bhavnagar which are for different products having a capacity of approx. 9,700 MTPA. Block 1- APIs, Block 2- Magnesium Hydroxide, Block 3- Fine Chemicals and Block 4- APIs/ Fine Chemicals. The Bhavnagar facility certified by food & drugs control administration. During the year 2011, the company has added two manufacturing block out of three at Chitra, Bhavnagar facility. One is dedicated facility for its main API and another one is for Fine Chemicals. The Product portfolio presently comprises 12 APIs and 6 Fine Chemicals which are marketed domestically and exported. The Key customers include Essential Drugs Company Limited, Taurus Chemicals (P) Limited, Pfizer Limited, United Phosphorus Limited(Samba Jammu Unit), Shiv Silica Private Limited. The Company raised money from public through IPO by issuing 16,72,000 Equity Shares aggregating to Rs 8.53 Crore in May, 2019. In June, 2021, the Company started a set of new production line-up i.e. one new manufacturing block, which increases production capacity within the existing product portfolio i.e. same as per existing product portfolio and market. There are four Manufacturing Blocks at Bhavnagar which are for different products having a capacity of approx 9,700 MTPA. Block 1 - APls, Block 2 - Magnesium Hydroxide, Block 3 - Fine Chemicals and Block 4 - APls/ Fine Chemicals.
Price Action • PAR
Financial Statements
Consolidated & Standalone Reports
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 | Mar '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 101.79 | 103.12 | 95.88 | 95.99 | 75.26 | 60.94 | 55.95 | 46.41 | 42.42 | 48.81 | 33.3 | 33.28 |
Operating Expenses | 84.93 | 81.47 | 72.82 | 77.54 | 58.82 | 44.74 | 46.4 | 38.13 | 34.4 | 40.3 | 25.84 | 25.87 |
Operating Profit | 13.48 | 19.5 | 22.82 | 18.21 | 16.25 | 16.01 | 9.45 | 8.2 | 7.98 | 8.46 | 7.43 | 7.37 |
Operating Margin (%) | - | 18.91 | 23.8 | 18.97 | 21.6 | 26.28 | 16.89 | 17.66 | 18.82 | 17.34 | 22.3 | 22.15 |
Total Expenses | - | 85.2 | 76.37 | 80.91 | 62.56 | 48.2 | 49.96 | 43.13 | 39.86 | 45.63 | 31.99 | 32.06 |
EBITDA | - | 21.65 | 23.06 | 18.45 | 16.44 | 16.2 | 9.55 | 8.28 | 8.02 | 8.5 | 7.46 | 7.41 |
EBITDA Margin (%) | - | 21 | 24.05 | 19.22 | 21.84 | 26.59 | 17.06 | 17.85 | 18.91 | 17.42 | 22.41 | 22.26 |
Interest Expenses | 0.1 | 0.08 | 0.11 | 0.13 | 0.45 | 0.64 | 0.79 | 1.96 | 2.33 | 2.5 | 3.5 | 3.86 |
Depreciation | 3.68 | 3.65 | 3.44 | 3.23 | 3.28 | 2.82 | 2.76 | 3.04 | 3.14 | 2.82 | 2.65 | 2.33 |
Profit Before Tax (PBT) | 13.08 | 17.92 | 19.52 | 15.08 | 12.7 | 12.74 | 5.99 | 3.28 | 2.55 | 3.18 | 1.31 | 1.22 |
Tax Expenses | 3.39 | 4.56 | 5.02 | 3.75 | 3.49 | 3.11 | 1.23 | 0.86 | 1.06 | 1.34 | 0.58 | 0.34 |
PAT Before Extraordinary Items | - | 13.36 | 14.5 | 11.33 | 9.21 | 9.63 | 4.76 | 2.42 | 1.5 | 1.85 | 0.73 | 0.89 |
Net Profit | 9.69 | 13.36 | 14.5 | 11.33 | 9.21 | 11.61 | 4.76 | 2.42 | 1.5 | 1.85 | 0.73 | 0.89 |
Net Profit Margin (%) | - | 13.22 | 15.16 | 11.83 | 12.27 | 19.11 | 8.53 | 5.22 | 3.52 | 3.78 | 2.2 | 2.66 |
EPS (Adjusted) | - | 10.86 | 11.79 | 9.21 | 7.49 | 9.44 | 3.87 | 1.97 | 1.22 | 1.5 | 0.6 | 0.72 |
Valuation & Key Ratios
Performance Metrics
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 | Mar '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Per Share | - | 80.44 | 69.59 | 57.9 | 48.66 | 84.87 | 66.02 | 64.99 | 55.36 | 49.83 | 44.42 | 41.76 |
Return on Assets (ROA) % | - | 11.18 | 14.27 | 12.75 | 11.7 | 15.2 | 7.92 | 4.7 | 2.77 | 3.29 | 1.26 | 1.51 |
Return on Equity (ROE) % | - | 13.49 | 16.93 | 15.91 | 15.38 | 22.23 | 11.73 | 8.3 | 10 | 13.73 | 6.1 | 7.86 |
Return on Capital Employed (ROCE) % | - | 17.51 | 22 | 20.31 | 20.61 | 22.15 | 13.77 | 13.48 | 13.1 | 15.59 | 13.54 | 12.82 |
Profitability Ratios | - | - | - | - | - | - | - | - | - | - | - | - |
Liquidity Ratios | - | - | - | - | - | - | - | - | - | - | - | - |
Valuation Ratios | - | - | - | - | - | - | - | - | - | - | - | - |
Debt to Equity Ratio | - | 0 | 0 | 0 | 0 | 0.15 | 0.11 | 0.36 | 1.21 | 1.55 | 2.15 | 2.47 |
Featured Insight
No recent news available
Key People
J
Jigneshbhai Vallabhbhai Savani
Executive Director,Chief Executive Officer
S
Sanket Bhupendrabhai Trivedi
Company Secretary,Compliance Officer
M
Mr. Chintan Pratapbhai Chauhan
Chief Financial Officer